Lenvenib 4mg Capsule 7s

Uses of Lenvenib 4mg Capsule 7s

Lenvatinib is a prescription medicine that is used to treat certain kinds of cancer. Lenvatinib is used to treat :
1. differentiated thyroid cancer (DTC) ,
2. advanced renal cell carcinoma (RCC)
3. liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery
4. Endometrial Carcinoma

Side Effects of Lenvenib 4mg Capsule 7s

The most common side effects of Lenvatinib include 1. Tiredness,
2. Joint and muscle pain, ,
3. Decreased appetite, weight loss, ,
4. Nausea, ,
5. Mouth sores, ,
6. Headache, ,
7. Vomiting, ,
8. Rash, redness, itching, or peeling of your skin on your hands and feet, ,
9. Stomach (abdomen) pain ,
10. Hoarseness.
Some of the serious side effects of Lenvatinib include :
1. High Blood Pressure
2. Heart Problems
3. Liver Problems
4. Kidney Problems
5. Increased protein in urine
6. Diarrhea
7. Bleeding
8. High Calcium level in blood (Hypercalcaemia)

Mechanism of Action

Lenvatininb inhibits the activity of enzyme Kinases which are responsible for growth of tumor cells thereby stops the progression of cancer cells.

Special Precautions

Lenvatinib should be used with caution in following conditions :
1. Hypertension: Control blood pressure prior to treatment and monitor during treatment. Withhold for Grade 3 hypertension despite optimal antihypertensive therapy.Discontinue for Grade 4 hypertension.
2. Cardiac Dysfunction: Monitor for clinical symptoms or signs of cardiac dysfunction. Withhold or discontinue for Grade 3 cardiac dysfunction. Discontinue for Grade 4 cardiac dysfunction.
3. Arterial Thromboembolic Events: Discontinue following an arterial thromboembolic event.
4. Hepatotoxicity: Monitor liver function prior to treatment and periodically during treatment. Withhold or discontinue for Grade 3 or 4 hepatotoxicity. Discontinue for hepatic failure.
5. Renal Failure or Impairment: Withhold or discontinue for Grade 3 or 4 renal failure or impairment.
6. Proteinuria: Monitor for proteinuria prior to treatment and periodically during treatment. Withhold for 2 or more grams of proteinuria per 24 hours. Discontinue for nephrotic syndrome.
7. Diarrhea: May be severe and recurrent. Promptly initiate management for severe diarrhea. Withhold or discontinue based on severity.
8. Fistula Formation and Gastrointestinal Perforation: Discontinue in patients who develop Grade 3 or 4 fistula or any Grade gastrointestinal perforation.
9. Hypocalcemia: Monitor blood calcium levels at least monthly and replace calcium as necessary. Withhold or discontinue based on severity.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.